Ravin J. Garg

发表

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high‐dose cytarabine chemotherapy

H. Kantarjian, F. Ravandi, S. Pierce, 2009, Cancer.

Tyrosine Kinase Inhibitors: The First Decade

J. Cortes, A. Quintás-Cardama, Meetu Agrawal, 2010, Current hematologic malignancy reports.

The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

L. Abruzzo, M. Keating, S. O'brien, 2012, Cancer.

Experimental therapeutics for patients with myeloproliferative neoplasias

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Cancer.

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.

Z. Estrov, H. Kantarjian, J. Cortes, 2009, Blood.

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.

Z. Estrov, H. Kantarjian, J. Cortes, 2009, Blood.

Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?

H. Kantarjian, J. Cortes, Meetu Agrawal, 2009, Current oncology reports.

Presenting comparative study PRO results to clinicians and researchers: beyond the eye of the beholder

B. Reeve, N. Aaronson, E. Bantug, 2017, Quality of Life Research.

Phase II Study of Dasatinib in Patients with Relapsed CLL

Z. Estrov, S. O'brien, W. Wierda, 2008 .